BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-86@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Sun Pharmaceutical Industries\, Inc. — CTP-543 [May 2027
 ]
DESCRIPTION:Phase 3 primary completion: Extension Study to Evaluate Safety 
 and Efficacy of CTP-543 in Adults With Alopecia Areata.\nSource: https://c
 linicaltrials.gov/study/NCT03898479\nhttps://catalystbrief.girapphe.com/e/
 86?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/86?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
